Last updated on June 2019

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Neoplasms | Unknown Primary
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Histologically-confirmed cancer of unknown primary site (CUP)(non-specific subset) according to criteria from the European Society for Medical Oncology, version 1 (ESMO v1)
  • Each patient must provide a blood sample for genomic profiling
  • No prior lines of systemic therapy for the treatment of CUP
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Candidate for platinum-based doublet chemotherapy (according to the reference information for the intended doublet therapy)
  • At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors, version 1.1 (RECIST v1.1)
  • Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue sample that is sufficient for generation of a comprehensive genomic profile at a central reference pathology laboratory

Exclusion Criteria:

  • Squamous cell CUP
  • History or known presence of leptomeningeal disease
  • Known human immunodeficiency virus (HIV) infection
  • Significant cardiovascular disease
  • Prior allogeneic stem cell or solid organ transplantation
  • Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or for up to 24 months after the last dose of study treatment

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.